Has Medhat Mikhael received payments from drug or device companies?

Yes. Drug and device makers reported $138,613 in general payments to Medhat Mikhael across 694 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Medhat Mikhael did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Medhat Mikhael come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Medhat Mikhael

Pain Medicine · Long Beach, CANPI 1558397331

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $92,550 of the $138,613 with a category attached, or 66.8%. Boston Scientific accounts for 68.1% of it on its own, with 57 other manufacturers making up the rest. Reporting peaked in 2019 at $43,852 and has fallen 98.7% since, to $578 in 2025. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$138,613in general payments, 2019–2025

Across 694 payments — averaging $199.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$94K
AbbVie$24K
Medtronic$9K
MDD US Operations, LLC$2K
Nevro Corp.$2K
Abbott$2K
plus $5K from 52 others

$98,746in research payments, 2019–2025

Across 40 payments — averaging $2468.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Seikagaku Corporation$79K
Boston Scientific$20K

What the payments were for

Consulting fees$15,92511%
Speaking & faculty fees$92,55067%
Travel & lodging$10,9508%
Food & beverage$19,17114%
Education$170%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	191	$94,410
AbbVie(2 entities)	151	$23,790
Medtronic(2 entities)	59	$9,120
MDD US Operations, LLC	8	$2,346
Nevro Corp.	22	$2,171
Abbott	55	$2,134
Amgen	12	$278
Pfizer	21	$275
Collegium Pharmaceutical, Inc.	17	$271
Vertiflex, Inc.	5	$266
Scilex Pharmaceuticals Inc.	14	$258
Saluda Medical Americas, Inc.	1	$209
West Therapeutics Development, LLC	11	$209
Biodelivery Sciences International, Inc.	18	$204
Pacira Therapeutics, Inc.	8	$195
Stimwave Technologies Incorporated	1	$180
Almatica Pharma LLC	7	$150
Acelrx Pharmaceuticals, Inc.	3	$144
Stryker	3	$130
Nalu Medical, Inc.	2	$115
GRT US Holding, Inc.	5	$115
Mallinckrodt Enterprises LLC	4	$111
Lilly USA, LLC	7	$99
Painteq LLC	3	$98
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$97
Piramal Critical Care	4	$90
Spinal Simplicity, LLC	3	$81
Fidia Pharma USA Inc.	5	$81
Novartis	4	$79
Biohaven Pharmaceutical Holding Company Ltd.	4	$75
Relievant Medsystems, Inc.	2	$74
Biohaven Pharmaceuticals, Inc.	3	$61
Curonix LLC	3	$59
Johnson & Johnson	2	$48
Teva Pharmaceuticals USA, Inc.	2	$47
Arbor Pharmaceuticals, Inc.	3	$43
Redhill Biopharma Inc.	2	$39
USWM, LLC	2	$36
Tersera Therapeutics LLC	2	$36
IBSA Pharma Inc.	2	$34
Forte Bio-pharma LLC	3	$33
Trevena, Inc.	2	$31
Biomarin Pharmaceutical Inc.	1	$27
Averitas Pharma Inc.	1	$24
Baxter Healthcare	1	$22
Sun Pharmaceutical Industries Inc.	1	$21
Kaleo, Inc.	1	$21
Xeris Pharmaceuticals, Inc.	1	$20
Si-bone, Inc.	1	$20
Pacira Pharmaceuticals Incorporated	1	$19
Vertos Medical, Inc.	1	$19
Daiichi Sankyo Inc.	1	$17
Hikma Pharmaceuticals USA	1	$16
Avanos Medical	1	$14
Zyla Life Sciences, Inc.	1	$14
SPR Therapeutics, Inc	1	$13
Assertio Therapeutics, Inc.	1	$12
AstraZeneca	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SPECTRA WAVEWRITER$41,177
UBRELVY$21,742
WAVEWRITER ALPHA$14,632
GENERAL PAIN MANAGEMENT$13,745
RESTORE$6,600
WaveWriter Alpha Prime 16$5,223
GENERAL - THERAPIES$4,156
Lucemyra/Lofexidine$2,250
Senza Spinal Cord Stimulation System$1,461
QULIPTA$720
Proclaim IPG$658
VANTA ADAPTIVESTIM$624
INTELLIS ADAPTIVESTIM$415
Proclaim Family of SCS IPGs$323
INTELLIS$273
PROCLAIM$249
Evoke$209
Vanta$161
Superion ISS$137
DSUVIA$124

How this compares

$138,613 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ulticare Pen NeedlePen Needle, Diabetic	12	$712
Gabapentin	13	$186

Paid to pharmacies, not to this prescriber.

Other pain medicine in Long Beach

Jason PopeSanta Rosa$2.1M
Ramana NaiduLarkspur$1.4M
Foead GeulaStudio City$1.3M
Krishnan ChakravarthyTemecula$1.3M
Kasra AmirdelfanWalnut Creek$783K
Eric GrigsbyNapa$499K
Jacqueline WeisbeinNapa$494K
Gerald SacksSanta Monica$389K
Samir ShethRoseville$356K
Einar OttestadStanford$352K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →